Cytiva Expands Cell and Gene Therapy Fast Trak Services
Cytiva is adding process development, media and assay development, and contract development services at its facilities in Korea, Japan, Sweden, and the UK.
Cytiva is expanding its offering at its Fast Trak research and training facilities in Korea; Japan; Cambridge, UK; and Uppsala, Sweden to support the growing cell and gene therapy industry, the company announced in a Dec. 9, 2020 press release. The company is adding process development, media and assay development, and contract development services for preclinical through Phase I manufacturing at these sites, complementing current services provided in Shanghai; Toronto; and Marlborough, MA.
According to the press release, each site will have space dedicated solely to cell and gene therapy process development and training and will use Cytiva’s digital technologies. Cytiva’s experts will work with customers to improve productivity and reduce costs, which will assist them in bringing their novel therapeutics to market faster, while maintaining complete control and understanding of their processes.
The sites will also offer specialized training and education with cell therapy manufacturing courses. Cytiva recently held its first in-person and online digital cell therapy training program, the company said in the press release. The online, self-paced Advanced Cell Therapy Technology CELLT1 program is divided into eight courses and covers upstream, cell expansion, and downstream applications. The program provides a comprehensive overview of the cell and gene therapy market through a combination of theoretical and lab-based learning.
Source: Cytiva
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
